Research Article
Adult Pleomorphic Rhabdomyosarcomas: Assessing Outcomes Associated with Radiotherapy and Chemotherapy Use in the National Cancer Database
Table 5
Factors associated with receipt of radiotherapy.
| | Receipt of radiotherapy | Univariate analysis | Multivariate analysis | | OR (95% CI) | value | OR (95% CI) | value |
| | Age | | <70 years | 1 | | 1 | | | ≥70 years | 0.62 (0.36–1.09) | 0.096 | 0.55 (0.30–1.00) | 0.052 | | Gender | | Male | 1 | | 1 | | | Female | 0.50 (0.29–0.87) | 0.014 | 0.40 (0.22–0.74) | 0.003 | | Race | | Non-Hispanic White | 1 | | — | — | | Non-Hispanic Black | 1.45 (0.53–4.00) | 0.471 | — | — | | Hispanic | 0.77 (0.27–2.21) | 0.621 | — | — | | Other | 4.02 (0.87–18.50) | 0.074 | — | — | | Facility area | | Metropolitan | 1 | | — | — | | Urban | 1.31 (0.53–3.21) | 0.556 | — | — | | Rural | 1.64 (0.31–8.66) | 0.562 | — | — | | Unknown | 1.64 (0.31–8.66) | 0.562 | — | — | | Facility location | | East | 1 | | — | — | | South | 0.61 (0.27–1.38) | 0.235 | — | — | | Central | 0.96 (0.40–2.28) | 0.922 | — | — | | West | 0.90 (0.37–2.15) | 0.808 | — | — | | Unknown | 1.53 (0.49–4.75) | 0.466 | — | — | | Facility type | | Non-academic | 1 | | — | — | | Academic | 1.14 (0.65–2.01) | 0.648 | — | — | | Insurance | | Commercial | 1 | | — | — | | Medicare | 0.77 (0.44–1.36) | 0.369 | — | — | | Medicaid | 2.39 (0.64–8.98) | 0.198 | — | — | | Uninsured | . | . | — | — | | Other | 1.49 (0.28–8.06) | 0.642 | — | — | | Distance to treatment facility | | ≤40 miles | 1 | | — | — | | >40 miles | 1.23 (0.67–2.23) | 0.503 | — | — | | Zip code education level | | ≥21% | 1 | | — | — | | 13%–20.9% | 0.83 (0.35–1.97) | 0.666 | — | — | | 7%–12.9% | 0.80 (0.35–1.84) | 0.598 | — | — | | <7% | 1.58 (0.66–3.82) | 0.307 | — | — | | Zip code income level | | <38,000 | 1 | | — | — | | 38,000–47,999 | 0.72 (0.30–1.72) | 0.460 | — | — | | 48,000–62,999 | 0.95 (0.42–2.15) | 0.896 | — | — | | ≥63,000 | 1.27 (0.55–2.91) | 0.572 | — | — | | Charlson/Deyo score | | 0 | 1 | | — | — | | 1 | 0.64 (0.30–1.37) | 0.256 | — | — | | 2 | 0.43 (0.09–1.97) | 0.274 | — | — | | 3 | 1.71 (0.17–16.74) | 0.646 | — | — | | Primary site | | Extremity | 1 | | 1 | | | Head and neck | 0.54 (0.16–1.80) | 0.314 | 0.45 (0.13–1.55) | 0.205 | | Thorax | 0.27 (0.11–0.67) | 0.005 | 0.21 (0.08–0.55) | 0.001 | | Abdomen/pelvis | 0.26 (0.13–0.52) | <0.001 | 0.22 (0.10–0.45) | <0.001 | | Other/NOS | 0.38 (0.02–6.30) | 0.503 | 0.20 (0.01–3.39) | 0.266 | | Tumor size | | <5 cm | 1 | | — | — | | 5.1–10 cm | 1.38 (0.69–2.79) | 0.366 | — | — | | 10.1–15 cm | 1.45 (0.63–3.34) | 0.385 | — | — | | >15 cm | 0.72 (0.30–1.74) | 0.470 | — | — | | Grade | | II | 1 | | — | — | | III | 1.37 (0.40–4.63) | 0.614 | — | — | | Receipt of chemotherapy | | No | 1 | | — | — | | Yes | 1.32 (0.76–2.27) | 0.321 | — | — | | Year of diagnosis | | 2004–2007 | 1 | | — | — | | 2008–2011 | 0.61 (0.31–1.20) | 0.151 | — | — | | 2012–2015 | 1.09 (0.56–2.11) | 0.806 | — | — |
|
|
